Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have received a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $22.25.

Separately, StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd.

Aclaris Therapeutics Stock Up 1.8 %

Shares of NASDAQ:ACRS opened at $1.15 on Friday. The company has a market cap of $81.95 million, a price-to-earnings ratio of -1.06 and a beta of 0.06. The firm’s 50-day simple moving average is $1.16 and its 200-day simple moving average is $1.16. Aclaris Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $11.12.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.04. The business had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.99 million. Aclaris Therapeutics had a negative net margin of 248.28% and a negative return on equity of 61.03%. On average, research analysts forecast that Aclaris Therapeutics will post -0.78 EPS for the current year.

Insiders Place Their Bets

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard bought 1,000,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was bought at an average price of $1.08 per share, for a total transaction of $1,080,000.00. Following the completion of the transaction, the insider now owns 10,395,934 shares in the company, valued at approximately $11,227,608.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders acquired 1,678,621 shares of company stock worth $1,857,414. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACRS. Vontobel Holding Ltd. grew its holdings in shares of Aclaris Therapeutics by 128.8% during the fourth quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock worth $32,000 after buying an additional 17,040 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Aclaris Therapeutics during the first quarter worth about $39,000. SG Americas Securities LLC grew its holdings in shares of Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after buying an additional 13,461 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Aclaris Therapeutics by 115.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock worth $46,000 after buying an additional 23,467 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of Aclaris Therapeutics by 5,265.1% during the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after buying an additional 61,602 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.